particularly when combined with similar toxicities of some of the anti-cancer chemotherapeutic agents, such as cisplatin, which is widely used in the treatment of solid tumours. In addition, because of the increased occurrence of Gram-positive infections, addition of a glycopeptide is often required, increasing both renal toxicity and cost of treatment.
Unlike the neutropenic episodes in patients with haematological malignancies, the episodes observed during the treatment of lymphomas, myelomas and solid tumours are characterized by a short and very similar duration (less than 1 week (median: 4 days) at the Centre Régional Léon Bérard in 1994). 6 Such short duration aplasia does not require systematic digestive decontamination and occurs predominantly after the patient's discharge. Monotherapy with a broad-spectrum -lactam antibiotic offers a good alternative to combination therapy in this low-risk patient population and has been increasingly suggested in recent years. The most frequently used drugs are ceftazidime, imipenem-cilastatin and, more recently, meropenem. [7] [8] [9] [10] [11] [12] The advantages of monotherapy with these agents, which have identical efficacy, are the lower toxicity, lower cost and ease of use. In this trial, we decided to compare cefepime with imipenem-cilastatin at the recommended dosage of 50 mg/kg/day for severe infections.
Cefepime is the first in a class of new broad-spectrum cephalosporins and has the characteristics required for initial empirical therapy of febrile episodes in neutropenic patients. 13, 14 Its spectrum of activity includes ceftazidimesusceptible Gram-negative bacilli and many Gramnegative bacilli resistant to ceftazidime and other expanded-spectrum cephalosporins. It is also more active than third-generation cephalosporins against Grampositive cocci, including streptococci and methicillinsusceptible staphylococci.
Three trials have evaluated the use of cefepime monotherapy in the treatment of febrile patients with neutropenia, and a fourth compared the efficacy of cefepime with that of ceftazidime, both in combination with amikacin. [15] [16] [17] [18] Based on more than 600 cefepime-treated episodes, these trials confirmed the efficacy of cefepime in the treatment of febrile episodes in neutropenic patients. However, they did not specifically evaluate patients with solid tumours, lymphomas or myelomas and were limited to a cefepime dosage of 6 g/day (or 4 g/day in combination with amikacin), mostly in patients with haematological malignancies with prolonged and profound neutropenia.
The present study was preceded by a pilot study 6 of 50 patients with short duration neutropenia treated with cefepime at the dosage of 2 g bd, whose results supported the choice of this dosage for the current trial. The results presented here are from the first multicentre study comparing cefepime 2 g bd with imipenem-cilastatin as initial monotherapy for febrile episodes in patients with neutropenia of short duration.
Materials and methods

Study design and entry criteria
This open multicentre comparative study was conducted in 17 French anti-cancer centres between April 1995 and November 1996, and comprised 400 febrile episodes occurring in 380 cancer patients. Patients were eligible if they were neutropenic within 1 month of treatment for a cancerous solid tumour, lymphoma or myeloma and if they had a fever attributable to an infectious episode. Neutropenia was defined by a neutrophil count of 1000/mm 3 and expected to be 500/mm 3 within 48 h of antibiotic treatment. Fever was defined as a temperature of 38.5°C or 38.0°C for at least 3 h. Patients were not included if they met any of the following criteria: previous systemic antibiotic therapy within 3 days; history of anaphylactic reaction to -lactams; pregnancy/nursing; renal insufficiency (dialysis or creatinine clearance 30 mL/min); digestive absorbable decontamination; or aplasia following stem cell reinfusion. Patients could be randomized twice into the trial if the initial antibiotic treatment had been completed 4 weeks earlier. Written informed consent was obtained from all patients. The protocol was approved by the Consultative Committee of Lyon, France.
Study schedule
Before the start of therapy, patients underwent a physical and clinical examination. A minimum of two blood samples for cultures were obtained and specimens were also collected from urine, throat, stool and any other appropriate site, as applicable. Samples were repeated during therapy as appropriate (at least by day 4) and on the last day of treatment, if eradication was not documented before this. All causative pathogens isolated were tested for their susceptibility to the study drugs. Haematological and chemical analyses were performed before therapy and repeated during and on the last day of therapy. Patients were monitored daily for clinical signs and symptoms and intercurrent events until the final evaluation, which was performed 7 days after completion of antibiotic treatment.
Randomization and treatment
Patients were randomized using a centralized computer network system, stratified by centre and by first or second inclusion. Patients were randomly assigned to receive either cefepime 2 g bd or imipenem-cilastatin 50 mg/kg/ day in three divided doses (mostly 1 g tds for 60 kg body weight). Patients were treated for a minimum of 4 days. Treatment could be stopped only after maintained apyrexia had been observed and after the neutrophil count had reached 500/mm 3 . For patients who did not respond after three full days of monotherapy, addition of appropriate antibiotics was allowed. In such cases, glycopeptides were recommended in the absence of positive cultures, while the choice of antibiotic was based on in-vitro sensitivity for documented infections.
Evaluation of efficacy
According to the guidelines issued by the Immunocompromised Host Society (IHS) consensus conference and the European Society of Clinical Microbiology and Infectious Disease (ESCMID), 3, 4 all patients for whom a causative pathogen was isolated were classified as microbiologically documented infections. Bacteraemia was considered present when at least one positive blood culture result was obtained, except for coagulase-negative staphylococci and other skin organisms for which at least two positive blood culture specimens were required. Urinary tract infection required the presence of 10 5 cfu/mL. Patients for whom no infecting organism could be isolated were considered to have clinically documented infections if they had fever and clinical evidence of infection (mucositis was not considered as evidence of infection). Finally, episodes without clinical or microbiological documentation were called fevers of unknown origin.
The therapeutic response was assessed in agreement with the IHS consensus conference and ESCMID guidelines, 3, 4 although any recurrence of fever or signs and symptoms until 7 days after therapy was considered as a failure, even in cases of new infection. Response to monotherapy was assessed 7 days after completion of treatment.
Response was classified as a success if all of the following criteria were met: apyrexia maintained; clinical signs and symptoms resolved, when applicable; all causative organisms eradicated, if any; no relapse or new infection by 7 days after therapy; survival with no other antibiotic added by day 7. Any episodes in which another antibiotic was added were classified as failure of monotherapy. Those patients were further assessed for their response to the anti-infective strategy using the above criteria (success with or without addition).
Patients were excluded from the efficacy analysis if they met any of the following criteria: documented fungal or viral initial infections; absence of fever or neutropenia as defined in the inclusion criteria; unjustified concomitant antibiotic; improper dosage or any protocol violation or event precluding evaluation; and premature discontinuation (except in the case of clinical worsening). All patients who received at least one dose of study drug were evaluable for safety analysis.
All 400 cases were reviewed by the Study Steering Committee (including clinicians and microbiologists) in a blinded fashion, without knowledge of the assigned treatment or the investigating centre, to determine evaluability, establish infectious diagnoses and evaluate response to treatment.
Statistical analysis
The primary analysis, on which sample size calculations were based, was a comparison of the rates of success with initial monotherapy, as assessed 7 days after therapy. The purpose of this trial was to determine whether monotherapy with cefepime was at least as effective as monotherapy with imipenem-cilastatin, using a unilateral equivalence analysis. 19 Assuming a clinical success rate of 60% for imipenem-cilastatin and accepting and error rates of 5% and 10%, respectively, and a theoretical confidence interval for acceptance of equivalence of 15%, 172 evaluable episodes were needed per treatment group. Based on an evaluability rate of 85%, it was postulated that 400 episodes needed to be studied. Secondary objectives included the comparison of success rates of the anti-infective strategy (success with or without addition) as well as of frequency of intercurrent events.
The comparability of treatment groups was verified on the 13 basis variables, using the t-test or Wilcoxon's rank sum test for quantitative variables and 2 or Fisher's exact test for qualitative variables. The equivalence of success rates was evaluated with the confidence interval method described by Rodary et al., 19 and the degree of significance was assessed using the Dunnet-Gent 2 test. A stratumadjusted analysis (first inclusion/second inclusion) was also performed, as well as a descriptive analysis on sub-groups corresponding to potential risk factors. Evaluations of survival and safety were performed for all treated patients and compared between treatment groups using the log rank test and the 2 test, respectively.
Results
Characteristics of study population
During the 18 month study period, 400 episodes occurring in 380 patients were randomized into the study (202 for cefepime and 198 for imipenem-cilastatin), of which 344 (86%) were evaluated for primary efficacy according to the Steering Committee blinded evaluation. The remaining 56 episodes were excluded for the following reasons: randomized and not treated (5); inclusion criteria violations (10); early discontinuation for reasons other than failure (24); improper dosage (4); and protocol violations or events precluding evaluation (13) . The characteristics of the 344 evaluable episodes, occurring in 328 patients, are summarized in Table I . There were no significant differences between the two groups in any of the characteristics, including age, sex, cancer disease type and status, and degree and duration of neutropenia. Three-quarters of the patients had solid tumours and more than half were receiving induction cancer chemotherapy. Two-thirds presented with profound neutropenia ( 100 neutrophils/mm 3 ) at entry. As expected, the duration of neutropenia was short (median: 4 days). The 344 episodes included 76 microbiologically documented infections, 19 clinically documented infections and 249 fevers of unknown origin, equally distributed between groups.
Of the 98 pathogens isolated in microbiologically documented infections, 45 (46%) were Gram-positive and 53 (54%) Gram-negative. The predominant pathogens were Escherichia coli (32), coagulase-negative staphylococci (18) , Staphylococcus aureus (12) , Pseudomonas aeruginosa (6) and Klebsiella spp. (6) . Ninety-two of the 98 pathogens were susceptible in vitro to cefepime and 93/98 to imipenem. All three methicillin-resistant staphylococci isolated were resistant to both study drugs. In addition, three enterococci were resistant to cefepime, while two of the six P. aeruginosa were resistant to imipenem and not to cefepime. Most of those pathogens were isolated from blood samples. Gram-positive species accounted for 58% of blood pathogens (30% coagulase-negative staphylococci) and the remaining 42% of Gram-negative species were mainly Enterobacteriaceae (30%).
Response to therapy
The median duration of treatment was 5.0 days for cefepime and 5.7 days for imipenem-cilastatin. The monotherapy response rate was 79% (139/177) in the cefepime group and 72% (121/167) in the imipenem-cilastatin group, demonstrating statistically significant equivalence (90% confidence interval: -1.6%, 13.6%; P 0.0001) ( Table II) . Equivalence of treatments was also demonstrated after adjustment on the first inclusion/second inclusion strata and, excluding the second inclusions, the The response rates were similar for all categories of febrile episodes, the highest being observed for fevers of unknown origin (cefepime, 86%; imipenem-cilastatin, 79%). For microbiologically documented infections, response to therapy was 66% for cefepime and 61% for imipenem-cilastatin. For bacteraemia, this response rate was similar in the cefepime group (63%) but was lower for imipenem-cilastatin (44%). Gram-positive bacteraemia was cured in 67% (10/15) of cefepime cases, compared with 38% (5/13) in the imipenem-cilastatin group, where most of the failures occurred on staphylococcal infections. For Gram-negative bacteraemia, success rates were 58% (7/12) for cefepime and 50% (6/12) for imipenemcilastatin, the failures mainly resulting from P. aeruginosa bacteraemia (1 and 4, respectively) . Apart from bactaeremia, none of the other factors studied were significantly associated with poor outcome (Table II) .
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The 84 failures of initial monotherapy were distributed as follows: (i) antibiotic was added for 35 patients in each group; (ii) there were seven post-therapy relapses/new infections in the imipenem-cilastatin group; (iii) treatment was changed in three patients in the cefepime group and one in the imipenem-cilastatin group; (iv) two patients in the imipenem-cilastatin group needed local surgery; and (v) one patient in the imipenem-cilastatin group died from infection. The 70 cases in which an antibiotic was added included 53 additions of glycopeptides, 19 of aminoglycosides, five of quinolones and one of a cephalosporin (78 antibiotics were added in 70 cases, because of eight simultaneous additions of two different antibiotics)
Overall, the response rate of the anti-infective strategy (taking into account all cases successfully treated with initial monotherapy or after addition of another antibiotic) was 95% for cefepime and 90% for imipenemcilastatin, demonstrating statistically significant equivalence (90% confidence interval: -0.3%, 9.3%; P 0.0001) ( Table III) . The final response rate of the anti-infective strategy for microbiologically documented infections was 94% and 81%, respectively. This response rate was higher for fevers of unknown origin, with 98% in the cefepime group and 94% in the imipenem-cilastatin group.
The global cost of antibiotic therapy was calculated for all patients who responded to the initial monotherapy, based on the acquisition cost of hospital antibiotics at the Central Hospital Pharmacy. The mean cost of studied antibiotic therapy per patient was 1486 French francs (equivalent to US$249) for cefepime and 2426 French francs (US$407) for imipenem-cilastatin. The global cost of anti-infective therapy was also calculated for all patients successfully treated after addition of another antibiotic. The mean cost of therapy per patient was 2945 French francs (US$494) for cefepime and 3677 French francs (US$616) for imipenem-cilastatin.
Survival
The overall survival rate at 7 days after therapy was 96% (381/395). There was no statistically significant difference between groups (cefepime, 95%; imipenem-cilastatin, 98%). Infectious mortality was uncommon: three (1.5%) of the cefepime patients and two (1%) of the imipenemcilastatin patients died. In the cefepime group, the three deaths involved one suspected intra-abdominal infection, one pneumonia (both without pathogen isolated) and one multiple organ failure in a patient with Enterobacter cloacae and Klebsiella pneumoniae bacteraemia. The two deaths in the imipenem-cilastatin group were caused by septic shock in patients with P. aeruginosa bacteraemia. Other causes of death included extensive cancer (six 
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Adverse events
The frequency of clinical intercurrent events possibly related to therapy was significantly lower in the cefepime group (18 (9%)) than in the imipenem-cilastatin group (38 (19%)) (P 0.003). Treatment discontinuation for such events occurred in three cefepime and four imipenemcilastatin cases. Nausea/vomiting was significantly more frequent in the imipenem-cilastatin group, both for all reported cases (imipenem-cilastatin, 39 (20%); cefepime, 18 (9%); P 0.002) and for possibly related cases (imipenem-cilastatin, 29 (15%); cefepime, 10 (5%); P 0.001). Other intercurrent events occurred at similar frequencies in the two groups ( 2%).
Discussion
Single-agent therapy is an attractive option for the empirical treatment of fever in neutropenic patients because such regimens generally cost less, are easier to administer and have more favourable side-effect profiles than combination regimens. A potential drawback, however, is the reduced spectrum of antimicrobial activity of single agents compared with multiple agents.
Because of its extended spectrum of activity, cefepime is an excellent candidate for use as empirical monotherapy. Recent studies have indicated that cefepime at a dosage of 2 g tds is effective as empirical treatment for febrile neutropenic patients. 15, 17, 18 Other agents that have also been successful in this setting include ceftazidime, imipenem-cilastatin and meropenem. [7] [8] [9] [10] [11] [12] The results of this study demonstrate that the clinical efficacy of cefepime is equivalent to that of imipenemcilastatin with respect to overall clinical success rate (79% vs 72%). However, patients with bacteraemia seemed to show a greater response to cefepime than to imipenemcilastatin (63% vs 44%), particularly for Gram-positive bacteraemia. As usually reported, results were better for fevers of unknown origin (86% vs 79%).
The majority of patients who were not cured by monotherapy responded to the addition of another drug, most frequently a glycopeptide, leading to an overall response rate of 95% for cefepime and 90% for imipenemcilastatin. Such a strategy led effectively to a decrease of the combinated toxicities of chemotherapeutic and antibiotic drugs along with a decrease of the treatment cost, as glycopeptides and/or aminoglycosides were added only in 20% of all cases. In addition, costs associated with cefepime treatment were approximately 60-80% of the costs incurred by regimens containing imipenem-cilastatin.
The analyses of safety data from the present trial found that cefepime was tolerated significantly better than imipenem-cilastatin (P 0.003), mainly because of the lower frequency of nausea and vomiting (P 0.001). The incidence of gastrointestinal toxicity in cefepime-treated patients in this study was lower than that previously reported in studies of cefepime monotherapy in neutropenic patients, 18 perhaps because of the decreased drug dosage (2 g bd rather than 2 g tds). Reduced gastrointestinal toxicity can be particularly important in patients receiving chemotherapy, as many chemotherapeutic agents induce nausea and vomiting. Furthermore, in this study, renal tolerance was excellent for both drugs.
On a theoretical point of view, this study is one of a few where acute haematological malignancies are not included with solid tumour patients. This results in a very homogeneous population of patients and duration of aplasia, leading to a powerful validation of empirical monotherapy in those patients.
In conclusion, both cefepime (2 g bd) and imipenem- cilastatin (1 g tds) demonstrate clinical effectiveness as empirical monotherapy for febrile episodes in adult patients with non-haematological malignancies experiencing short-duration neutropenia. These results validate the use of empirical monotherapy, other antibiotics being added in only 20% of all cases, leading to overall success of this anti-infective strategy in 90% of all cases. Although the clinical efficacies of the two regimens were equivalent, cefepime was associated with significantly fewer episodes of drug-related toxicity as well as lower treatment-related costs. The efficacy, safety and extended spectrum of activity of cefepime thus support its use as empirical monotherapy in febrile, neutropenic patients with non-haematological malignancies.
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